In silico drug revelation administrations market is probably going to be worth USD 124 million by 2030, developing at an annualized pace of 15.6%, claims Roots Analysis
Roots Analysis has announced the
addition of “In Silico / Computer-Aided Drug Discovery Services Market: Focus on
Large Molecules (Antibodies, Proteins, Peptides, Nucleic Acid, Gene Therapy and
Vectors), 2020-2030 (Including Structure Based Drug Discovery, Fragment Based
Drug Discovery, Ligand Based Drug Discovery, Target Based Drug Discovery /
Multi-Target Drug Design, Interface Based Drug Discovery, Approaches)” report to
its list of offerings.
Presently, in silico tools / approaches are
available for the identification, selection and optimization of pharmacological
leads. in fact, the predictive power of such solutions has been demonstrated to
enable researchers to bypass the traditional experimental screening of billions
of molecules against hundreds of biological targets, thereby, allowing
significant reductions in the investment of both time and resources.
To order this 290+ page report, which features 120+ figures
and 130+ tables, please visit this
-https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html
Key Market Insights
Over 90 players
currently claim to provide In Silico drug discovery services for biologics
More than 70% of
these are small and mid-sized firms. Further, close to 60% of the CROs engaged
in this domain, claim to provide services to both pharmaceutical companies and
academic institutes. It is worth mentioning that about 30% of players presently
offer end-to-end drug discovery services
Over 150 software
solutions are currently available for use in drug discovery
Around 90 companies
are currently providing software tools, web applications and other technology
platforms for drug discovery. Examples of popular softwares include (in
alphabetical order) FORECASTER SUITE, MOPAC2016™, PKPlus™, REAL Space
Navigator, SaaS Platform and VolSurf+.
Nearly 80% of in
silico
drug discovery service providers are based in the developed geographies
This can be
attributed to the relatively high adoption of the In Silico approach by
players based in Europe and North America. On the other hand, there are
companies that are using this approach for drug discovery operations, in
emerging regions, such as India and China, as well.
Around 40% of the companies claim to specialize in antibodies, proteins and peptides
Within the antibodies
segment, nearly 60% of In Silico service offerings are focused on the
discovery of monoclonal antibodies. This is followed by companies providing services
for antibody fragments (43%), bispecific antibodies (34%) and polyclonal
antibodies (26%).
To request a sample copy / brochure of this
report, please visit this - https://www.rootsanalysis.com/reports/298/request-sample.html
Key
Questions Answered
§ Who
are the leading in silico service providers for discovery of different
types of large molecule drugs?
§ What
are the key challenges associated with the discovery of large molecule drugs?
§ What
is the likely cost saving opportunity associated with the use of in silico tools?
§ What
are the key computational approaches being used by in silico service
providers for drug discovery operations?
§ What
are the popular business strategies being used by in
silico drug
discovery service providers?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 124 million (by 2030) financial opportunity
within the in silico drug discovery market for large molecules has been analyzed
across the following segments:
§ Key
Drug Discovery Steps
§ Target
Identification
§ Target
Validation
§ Hit
Generation
§ Hit-to-Lead
§ Lead
Optimization
§ Type
of Large Molecule
§ Antibodies
§ Proteins
§ Peptides
§ Nucleic
Acids
§ Vectors
§
Company Size
§ Small
§ Mid-sized
§ Large
§ Target
therapeutic Area
§ Autoimmune
Disorders
§ Blood
Disorders
§ Cardiovascular
Disorders
§ Gastrointestinal
and Digestive Disorders
§ Hormonal
Disorders
§ Human
Immunodeficiency Virus (HIV) / Acquired Immunodeficiency Syndrome (AIDS)
§ Infectious
Diseases
§ Metabolic
Disorders
§ Mental
Disorders
§ Musculoskeletal
Disorders
§ Neurological
Disorders
§ Oncological
Disorders
§ Respiratory
Disorders
§ Skin
Disorders
§ Urogenital
Disorders
§ Others
§ Type
of Sponsor
§ Industry
Players
§ Non-Industry
Players
§ Key
Geographical Regions
§ North
America
§ Europe
§ Asia-Pacific
The report features
inputs from eminent industry stakeholders, according to whom the in silico approaches
significantly simplifies the drug discovery process, offering better screening
accuracy, as well as enabling innovators to reduce wet-lab efforts. The report
includes detailed transcripts of discussions held with the following experts:
§ John
L Kulp (Chief Executive Officer and Chief Technical Officer, Conifer Point Pharmaceuticals)
§ Sven
Benson (Founder, candidum)
§ Mark
Whittaker (Senior Vice President, Evotec)
§ Edelmiro
Moman (Scientific Consultant and Teacher, ProSciens)
The research covers
brief profiles of several companies (including those listed below); each
profile features an overview of the company, financial information (if
available), in silico-based service(s) portfolio and an
informed future outlook.
§ Abzena
§ BioDuro
§ BioNTech
§ ChemPartner
§ Creative
Biostructure
§ GenScript
§ LakePharma
§ Sundia
MediTech
§ Sygnature
Discovery
§ Viva
Biotech
For additional
details, please visit
https://www.rootsanalysis.com/reports/view_document/in-silico-drug-discovery/298.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
DNA-Encoded Libraries: Platforms and
Services Market
2.
Global Stem Cells
Market: Focus on Clinical Therapies, 2020–2030
3.
Companion Diagnostics
Services
Market, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Comments
Post a Comment